Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Multi-Indication Pricing: Big Hurdles And Actionable Options

Executive Summary

Pricing drugs differently by indication presents an opportunity to better align the cost of medicines to value in certain cases, but the regulatory, policy and administrative challenges are daunting. Experts debated the challenges and opportunities during the ISPOR annual meeting.


Related Content

Express Scripts Adds Gilead’s Harvoni To 2017 Formularies
Oncology Booming But Cost Outlook Grim, IMS Says
FDA Orphan-Only Review Division Could Speed Access, Gottlieb Suggests
Sanofi/Genzyme Primed Patient Community For Campath’s Removal From Commercial Distribution


Related Companies